title: Reply by the authors.
authors.affiliation: Office of Hematology and Oncology Products, U.S. Food and Drug Administration, Silver Spring, MD.
authors.forename: Jonathan P
authors.initials: JP
authors.lastname: Jarow
authors.affiliation: University of Texas Health Science Center, San Antonio, TX.
authors.forename: Ian M
authors.initials: IM
authors.lastname: Thompson
mesh_terms: D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000628:therapy*